Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#2815 Unexpected High Rate of Metastases in Type 1 Gastric Neuroendocrine Neoplasia
Introduction: Gastric neuroendocrine neoplasms (gNEN) represent about 7.5% of gastroenteropancreatic NEN (gepNEN), classified in: type 1 (70-80%), related to autoimmune gastritis, type 2 (5%), related to Zollinger-Ellison syndrome in multiple endocrine neoplasia 1 and type 3 (15-20%), in absence of hypergastrinemia or mucosal atrophy.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Bottiglieri F, Modica R, de Cicco F, Minotta R, Faggiano A,
Keywords: gastric, neuroendocrine, type1, type3, metastases,
Introduction: Data specific to sporadic neuroendocrine neoplasms (NEN) in young adult patients (pts) are limited due to its rare occurrence.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Altieri B
Authors: Altieri B, Modica R, Bottiglieri F, de Cicco F, Faggiano A,
Keywords: neuroendocrine neoplasms, young patients, age, natural history, treatment, prognosis,
Introduction: Patients with sporadic gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) may exhibit a higher risk of second primary tumors than the general population.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Massironi S
Authors: Massironi S, Campana D, Pusceddu S, Albertelli M, Faggiano A,
Keywords: GEP-NEN, Second primary neoplasm (PMN), Overall survival (OS),
Introduction: Many different therapies are suggested by guidelines to treat loco-regionally advanced or metastatic G1-G2 neuroendocrine tumors (NETs). However, a precise therapeutic algorithm has not yet been established.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Faggiano A, Di Maio S, Tafuto S, Mocerino C, Di Sarno A,
Keywords: neuroendocrine tumor, medical therapy, sequence of treatments,
Introduction: To date no systematic prospective trials have been carried out to evaluate safety and efficacy of unconventional doses of somatostatin analogs (SSAs) in neuroendocrine tumors (NETs). However,dose escalation of SSAs is a common strategy.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Albertelli M, Campana D, Faggiano A, Spada F, Baldelli R,
Keywords: SSA high dose,